Clinical Study
Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)
Table 3
Distribution of major anticholinergic adverse events in each group over 52 weeks.
| ||||||||||||||||||||||||||||||||||||||||||||
The severity of dry mouth was evaluated on a 3-point scale: mild, barely noticeable; moderate, tolerable after drinking water; severe, intolerable after drinking water, leading to discontinuation of the investigational drug; a: Mann-Whitney U test, b: Fisher exact test, two-sided. |